NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)-- #tech--Perion Network Ltd. (NASDAQ and TASE: PERI), a leader in advanced technology solving for the complexities of modern advertising, announced today that it will participate in the 20th Annual Needham Technology, Media & Consumer 1x1 Conference on May 13th in New York, and in the Oppenheimer 26th Annual Israeli Conference on May 18th in Israel. Tal Jacobson, CEO, and Elad Tzubey, CFO will host one-on-one meetings with investors. To schedule a meetin.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product.

CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net earnings of $295 million, adjusted net earnings1 of $338 million Earnings per share2 of $0.61, with adjusted EPS1,2 of $0.70, both down versus the prior year quarter Trailing four-quarter average return on invested capital (ROIC) of 5.4%, trailing four-quarter average adjusted ROIC1 of 7.0% Cash flows used in operating activities were $(342) mi.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2025. “We continue to execute across the portfolio as we work towards submitting the veligrotug BLA in the second half of 2025, advancing our VRDN-003 subcutaneous clinical tri.

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Dream Finders Homes, Inc. (the “Company”, “Dream Finders Homes”, “Dream Finders” or “DFH”) (NYSE: DFH) announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights (As Compared to First Quarter 2024) Homebuilding revenues increased 18% to $970 million from $825 million Home closings increased 16% to 1,925 from 1,655 Net new orders increased 18% to 2,032 from 1,724 Homebuilding gross margin of 19.2% compared to 17.

CHICAGO--(BUSINESS WIRE)--Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today introduced the Morningstar Medalist Rating™ for Semiliquid Funds, expanding its established Medalist Rating framework to the growing segment of semiliquid investment vehicles. As public and private markets converge and product offerings become more complex, the new rating brings greater transparency and due diligence to private markets. "Semiliquid funds are becoming more acc.

TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global energy and compute infrastructure company, today announced its participation in several upcoming investor and industry conferences.

TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce that McEwen Mining (“MUX”) has exercised 9,200,000 common share purchase warrants as part of the early warrant exercise incentive program for gross proceeds of $828,000. Proceeds from the warrant exercise will be used to advance the Company's 2025 bulk sampling program at its 100%-owned Pardo Gold Project, located 65 km northeast of Sudbury, Ontario.

ADDISON, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announces that CECO management will participate at the following investor conferences:

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Presented in Second Half of 2025 Ended First Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities, …

License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas , May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity.

Fund offers access to private venture and growth investments including disruptive technologies and innovative businesses CONSHOHOCKEN, Pa. , May 6, 2025 /PRNewswire/ -- Leading private markets investment firm Hamilton Lane (Nasdaq: HLNE) today announced the launch of the Hamilton Lane Venture Capital and Growth Fund ("HLVCG" or "the Fund"), a continuously offered evergreen investment vehicle registered under the Investment Act of 1940 ("40 Act"), available to accredited U.S. investor clients, including high-net-worth investors and their advisors2, as well as institutional investors.

OTTAWA, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world's largest and most innovative satellite operators, today announced its financial results for the three month period ended March 31, 2025. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted.

– Quarterly Revenue of $80.4 million – – Gross Margin of 35.0% – – Net Loss of $(0.3) million – – Adjusted EBITDA1 of $12.8 million – – Backlog and Awarded Orders Increased 5% Year-Over-Year to $645.1 million – – Provides Second Quarter and Full Year 2025 Outlook – PORTLAND, Tenn., May 06, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components, including battery energy storage solutions (“BESS”) and Original Equipment Manufacturer (“OEM”) components for the global energy transition market, today announced results …

ATLANTA, May 06, 2025 (GLOBE NEWSWIRE) -- Advanced Aesthetics Plastic Surgery has joined Ascend Aesthetic Partners, forming a partnership rooted in shared values of collaboration, clinical excellence, and continuous learning. With the addition of Dr. Joseph Raniere, Jr., Dr. Edward S. Gronka, and Dr. Takintope Akinbiyi as Partner Physicians, as well as Amanda Fowler, PA-C, Ascend now includes 24 physicians across six states—and a growing community—working together to advance the field of aesthetic medicine.

First Quarter 2025 Revenue of $49m, up 16% quarter over quarter Signed term sheet with Fortress Credit Advisors to serve as the JV financing partner at Barber Lake Nearing completion of 150 MW Phase I infrastructure at Black Pearl First Quarter 2025 GAAP Net Loss of $39m, and Non-GAAP Adjusted Earnings of $6m NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced its first quarter 2025 financial results, with an update on its operations and business strategy. “The first quarter was marked by disciplined execution and steady progress as we …

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe …

Total revenues increased 16.4% Net loss of $(0.8) million and Adjusted EBITDA of $22.8 million 13 new system-wide restaurants opened in 10 states

Engineering delivers strong year-over-year gains and internal growth First quarter operating highlights: Three months ended March 31 (in millions of US$, except EPS) 2025 2024 Revenues $ 1,141.2 $ 1,002.0 Adjusted EBITDA (note 1) 116.0 108.7 Adjusted EPS (note 2) 0.87 0.77 GAAP operating earnings 31.6 43.3 GAAP diluted net earnings (loss) per share (0.08 ) 0.26 TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers” or the “Company”) today announced financial results for the first quarter ended March 31, 2025. All amounts are in US dollars.